ArticleEuropean urology2022
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.The Journal of urology · 2023Guideline
- Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio.European radiology · 2026Trial
- Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.The Journal of urology · 2026Trial
- Comparing Regional Saturation Biopsy and Targeted Biopsy: Is Perilesional Biopsy Necessary for High-Prostate-Specific Antigen Patients?Annals of surgical oncology · 2026Trial
- Optimized Biopsy Strategy for Transition Zone Prostate Cancer With Enhanced Perilesional Sampling: A Retrospective Analysis and Clinical Trial Validation.JCO precision oncology · 2025Trial
- The learning curve for robotic-assisted transperineal MRI/US fusion-guided prostate biopsy.Scientific reports · 2024Trial
- Full-Field Optical Coherence Tomography for Immediate Analysis of Prostate Biopsy Cores: A New Step toward Real-Time Cancer Diagnosis.Annals of surgical oncology · 2026Article
- Prostate biopsy - current discussions and future perspectives.Prostate cancer and prostatic diseases · 2026Review
- Systematic versus perilesional sampling in transperineal MRI-fusion biopsy: is perilesional sampling ready for prime time? A high-volume center analysis.World journal of surgical oncology · 2026Article
- Prostate MRI reporting and its impact on clinical decision-making: the urologists' perspective.Abdominal radiology (New York) · 2026Review
- Impact of omitting contralateral systematic biopsy on clinically significant upgrading at radical prostatectomy: a retrospective paired-design study.International urology and nephrology · 2026Article
- Spatial Distribution of Prostate Cancer Missed by MRI-Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort.The Prostate · 2026Article
- Urologist and radiologist contributions to variation in prostate cancer detection at fusion biopsy.BJU international · 2026Article
- Navigating PI-RADS v2.1 in clinical practice: pitfalls, variability, and the supportive role of AI.Abdominal radiology (New York) · 2026Review
- Article
- Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches.Cancers · 2026Review
- Implications for Radiation Microboosting Based on Pathology Correlations With Prostate-Specific Membrane Antigen and Multiparametric Magnetic Resonance Imaging Findings.Advances in radiation oncology · 2026Article
- Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundSystematic prostate biopsies add to the cancer detection rate of targeted biopsies, but the explanation for that increased sensitivity is not yet clear.
objectiveTo determine and quantify the utility of perilesional biopsies in the detection of clinically significant prostate cancer (csPCa). DESIGN, SETTING, AND
participantsParticipants were 2048 men with magnetic resonance imaging (MRI) lesions (grades 3-5) who underwent targeted and systematic prostate biopsy via MRI/ultrasound fusion at University of California Los Angeles and Cornell between 2011 and 2019. The study is a retrospective examination of prospectively acquired data. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All biopsy cores (30191), locations of which had been stored digitally in the image-fusion device, were analyzed for tissue pathology and relationship with MRI lesions. A validated Matlab script was used to determine the distance between MRI lesions and cores containing csPCa (3552 cores from 927 men). Significance of distance measurements was determined by multilevel, multivariable logistic regression to account for within patient-biopsy correlation and control for patient characteristics. RESULTS AND LIMITATIONS: Overall, 90% (95% confidence interval [CI] = 89-91) of csPCa cores (3206/3552) were located within a radius of 10 mm from the nearest lesion: 65% (95% CI = 63-67) within the region of interest (ROI) and 26% (95% CI = 24-27) outside the ROI but within the 10-mm "penumbra." The width of the penumbra or concentric band, which enclosed 90% of csPCa, was primarily related to MRI grade of lesion: grade 5, 5 mm; grade 4, 12 mm; grade 3, 16 mm. In 18% (95% CI = 15-20) of patients (166/927), csPCa was diagnosed only by sampling outside the MRI lesion, the yield decreasing with increasing distance. Limitations of MRI interpretation and fusion biopsy performance could affect the utility of these data in individual patients.
conclusionsPerilesional biopsies, that is, samples taken from a band of 10-mm radius outside MRI lesions (the penumbra), contain most cores of csPCa that are not present within the lesion. These data may help increase the performance characteristics of targeted prostate biopsy. PATIENT SUMMARY: We studied the locations of cancer within the prostate in men undergoing magnetic resonance imaging (MRI)-guided biopsy. We found that not all cancers are located within the MRI lesion, but 90% (95% confidence interval = 89-91) of the cancers arewithin 1 cm of the lesions. Biopsies taken from both within and around MRI lesions provide greater sensitivity for cancer detection than samples taken from the lesion only.
Indexed as
Identifiers
35115177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.